MD Anderson-led Phase I trial of Adaptimmune T-cell receptor therapy sees confirmed responses in multiple cancer types HOUSTON ― The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses […]


